See our article on Why Laboratories Choose Palmetto Peptides for BPC-157 and TB-500 for details on our shipping and quality protocols
Multiple pathways offer comprehensive approach
To meet the diagnostic criteria for kEDS, a person must meet: Major criterion 1 AND major criterion 2 AND major criterion 3 OR Major criterion 1 AND major criterion 2 AND three minor criteria (general or gene-specific) Major Criteria Congenital muscle hypotonia Congenital or early onset kyphoscoliosis (progressive or non-progressive) Generalized joint hypermobility with dislocations/subluxations (shoulders, hips, and knees in particular) Minor Criteria Skin hyperextensibility Easily bruisable skin Rupture/aneurysm of a medium-sized artery Osteopenia/osteoporosis Blue sclerae Hernia (umbilical or inguinal) Pectus deformity Marfanoid habitus Talipes equinovarus Refractive errors (myopia, hypermetropia) Gene-Specific Minor Criteria PLOD1 Skin fragility (easy bruising, friable skin, poor wound healing, widened atrophic scarring) Scleral and ocular fragility/rupture Microcornea Facial dysmorphology FKBP14 Congenital hearing impairment (sensorineural, conductive, or mixed) Follicular hyperkeratosis Muscle atrophy Bladder diverticula Musculocontractural EDS (mcEDS) If a person meets the diagnostic criteria for mcEDS, genetic testing should be done to confirm the diagnosis
Other syntheses show earlier decline
semaglutide reconstitution Both are GLP-1 receptor agonists used in weight management research
Its been studied for its ability to: Support tendon and ligament repair Improve angiogenesis (formation of new blood vessels) Reduce inflammation in the gut and liver Possibly influence neurotransmitter systems like serotonin and dopamine While most studies are in animals, these pathways overlap with some of the most challenging aspects of menopause
